+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study



Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study



Critical Care Medicine 36(3): 807-811



The emergence of multidrug-resistant gram-negative bacteria has led to the re-use of colistin, but resistance to this agent has already been reported. We aimed to investigate the potential risk factors for the isolation of colistin-resistant Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa from hospitalized patients. Matched case-control study. Tertiary care hospital in Athens, Greece. Case patients were those who had provided a clinical specimen from which a colistin-resistant K. pneumoniae, A. baumannii, or P. aeruginosa was isolated. Controls were selected from a pool of patients who had susceptible to colistin isolates and were matched (1:1) to cases for species of microorganism and site of isolation. Susceptibility to colistin was determined with the Etest. None. Data regarding patient demographics, comorbidities, admission to the intensive care unit, prior antibiotic use, and invasive procedures performed were analyzed as risk factors in a matched bivariable model. Variables significantly associated with colistin-resistant isolates (p < .05) were entered in a backward multivariable logistic regression model. Forty-one colistin-resistant unique patient isolates were identified from January 1, 2006, until March 31, 2007. These isolates represented infection in 35 of 41 patients. Risk factors significantly associated with the isolation of colistin-resistant isolates were age, duration of intensive care unit stay, [corrected] surgical procedures, use of colistin, use of monobactams, duration of use of colistin and duration of use of antifungal agents [corrected] In the multivariable model, use of colistin was identified as the only independent risk factor (adjusted odds ratio = 7.78, p = .002). Colistin-resistant K. pneumoniae, A. baumannii, and P. aeruginosa pathogens may be encountered in clinical practice, in association with inappropriate colistin use. To prevent this phenomenon, colistin should be used judiciously, given that treatment options for colistin-resistant gram-negative bacteria are limited.

(PDF emailed within 0-6 h: $19.90)

Accession: 055579902

Download citation: RISBibTeXText

PMID: 18431267

DOI: 10.1097/CCM.0B013E3181652FAE


Related references

Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study. Journal of Microbiology, Immunology, and Infection 51(5): 621-628, 2017

Case control study of risk factors rf for nosocomial infection with fluoroquinolone fq and aminoglycoside ag resistant gram negative bacteria. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 216, 1992

Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. Journal of Clinical Microbiology 48(6): 2271-2274, 2010

Risk factors for colistin-resistant Enterobacteriaceae in a low-endemicity setting for carbapenem resistance - a matched case-control study. Euro Surveillance 23(30), 2018

Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study. Annals of Saudi Medicine 36(3): 216-222, 2017

Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria. Journal of ChemoTherapy 26(4): 211-216, 2015

Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series. ChemoTherapy 61(4): 190-196, 2016

Efflux pump inhibitor CCCP to rescue colistin susceptibility in mcr-1 plasmid-mediated colistin-resistant strains and Gram-negative bacteria. Journal of Antimicrobial ChemoTherapy 2018, 2018

Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors. Infection 41(6): 1195-1198, 2014

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet. Infectious Diseases 18(4): 391-400, 2018

Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respiratory Medicine 102(3): 407-412, 2007

Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review. Infection 42(5): 801-809, 2015

Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infection Control and Hospital Epidemiology 18(12): 809-813, 1998

Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clinical Microbiology and Infection 21(12): 1106.E1-8, 2016

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents 25(1): 11-25, 2004